CFO transition
ImageneBio, Inc. CFO transition: Yanina Grant-Huerta to succeed Kristin Yarema, Ph.D.
ImageneBio, Inc. reported in a Form 8-K filed July 23, 2026 that Yanina Grant-Huerta will succeed Kristin Yarema, Ph.D. as Chief Financial Officer, principal financial officer and principal accounting officer, effective July 20, 2026.
In the filing's words
On July 20, 2026, ImageneBio, Inc., a Delaware corporation (the “Company”), based in part on the recommendation of Kristin Yarema, Ph.D., the Company’s Chief Executive Officer, appointed Yanina Grant-Huerta as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective July 20, 2026.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | ImageneBio, Inc. (IMA) |
|---|---|
| Event | Transition |
| Incoming | Yanina Grant-Huerta |
| Outgoing | Kristin Yarema, Ph.D. |
| Title in the filing | Chief Financial Officer, principal financial officer and principal accounting officer |
| Effective | July 20, 2026 |
| 8-K filed | July 23, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Accounting Officer, Atara Biotherapeutics, Inc. |
| SEC CIK | 0001835579 |
ImageneBio, Inc. reported this change in a Form 8-K, Item 5.02, filed July 23, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Yanina Grant-Huerta? Send a correction with the primary source.